Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ardelyx Inc. ARDX

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with...


Recent & Breaking News (NDAQ:ARDX)

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire 3 days ago

Ardelyx to Participate in Upcoming Investor Conferences

PR Newswire September 6, 2022

Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PR Newswire August 4, 2022

Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference

PR Newswire August 2, 2022

Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022

PR Newswire July 28, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ardelyx, Inc.

Newsfile July 22, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire July 1, 2022

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

PR Newswire June 30, 2022

Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022

PR Newswire June 21, 2022

Ardelyx to Present at the Jefferies 2022 Healthcare Conference

PR Newswire June 3, 2022

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

PR Newswire May 24, 2022

Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

PR Newswire May 17, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire May 16, 2022

Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights

PR Newswire May 5, 2022

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

GlobeNewswire May 2, 2022

Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022

PR Newswire April 28, 2022

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)

PR Newswire April 25, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

PR Newswire April 12, 2022

Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor

PR Newswire April 11, 2022

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings

PR Newswire April 7, 2022